Syn2bio (WAR:S2B) Beginning Cash Position: zł7.06 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
9 GF Score
Price zł64.00
! 1 Warning Sign
View Full Analysis

What is Syn2bio Beginning Cash Position?

Syn2bio WAR:S2B -0.44% 9 Beginning Cash Position is zł7.06 Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Syn2bio's Beginning Cash Position for the quarter that ended in Sep. 2025 was zł7.06 Mil.

Syn2bio's quarterly Beginning Cash Position increased from Sep. 2023 (zł4.21 Mil) to Sep. 2024 (zł5.98 Mil) and increased from Sep. 2024 (zł5.98 Mil) to Sep. 2025 (zł7.06 Mil).

Syn2bio's annual Beginning Cash Position increased from Sep. 2023 (zł4.21 Mil) to Sep. 2024 (zł5.98 Mil) and increased from Sep. 2024 (zł5.98 Mil) to Sep. 2025 (zł7.06 Mil).

Syn2bio Beginning Cash Position Related Terms

Syn2bio Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Syn2bio's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Beginning Cash Position Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Beginning Cash Position
4.21 5.98 7.06

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Beginning Cash Position 4.21 5.98 7.06
WAR:S2B
9GF Score
Syn2bio SA WAR:S2B
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of zł7.06 Mil mean?
Syn2bio (WAR:S2B) has a Beginning Cash Position of zł7.06 Mil as of Sep. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Syn2bio and its competitors.
Is Syn2bio's Beginning Cash Position too high?
Syn2bio's current Beginning Cash Position is zł7.06 Mil. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Beginning Cash Position compare to VRTX and REGN?
Syn2bio's Beginning Cash Position of zł7.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Syn2bio and its competitors. Syn2bio's current Beginning Cash Position is zł7.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Beginning Cash Position of zł7.06 Mil. The current Beginning Cash Position is zł7.06 Mil. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Beginning Cash Position is zł7.06 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score

Get the complete analysis for WAR:S2B

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł64.00
Price